C4 Therapeutics Inc. (NASDAQ: CCCC) reported results from its Phase 1 trial of cemsidomide for treating relapsed/refractory multiple myeloma. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE